Toll Like Receptor 4 (hToll or CD284 or TLR4) - Pipeline Review, H2 2018

Publisher Name :
Date: 10-Jul-2018
No. of pages: 134

Toll Like Receptor 4 (hToll or CD284 or TLR4) - Pipeline Review, H2 2018

Summary

Toll Like Receptor 4 (hToll or CD284 or TLR4) - Toll-like receptor 4 is a protein encoded by the TLR4 gene. This receptor is mostly expressed in placenta, and in myelomonocytic subpopulation of the leukocytes. It is involved in LPS-independent inflammatory responses triggered by free fatty acids, such as palmitate, and Ni2+. It responses are triggered by Ni2+ require non-conserved. In complex with TLR6 promotes sterile inflammation in monocytes in response to oxidized low-density lipoprotein (oxLDL).

Toll Like Receptor 4 (hToll or CD284 or TLR4) pipeline Target constitutes close to 44 molecules. Out of which approximately 34 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 9, 4, 16 and 4 respectively.

Similarly, the universities portfolio in Preclinical and Discovery stages comprises 8 and 2 molecules, respectively. Report covers products from therapy areas Oncology, Infectious Disease, Gastrointestinal, Central Nervous System, Immunology, Cardiovascular, Dermatology, Ear Nose Throat Disorders, Genito Urinary System And Sex Hormones, Respiratory, Mouth and Dental Disorders, Musculoskeletal Disorders, Ophthalmology and Other Diseases which include indications Non-Alcoholic Steatohepatitis (NASH), Autoimmune Hepatitis, Inflammation, Liver Fibrosis, Sepsis, Atherosclerosis, Atopic Dermatitis, Breast Cancer, Dengue Fever, Drug Addiction, Kidney Fibrosis, Rheumatoid Arthritis, Soft Tissue Sarcoma, Traumatic Brain Injury, Acute Ischemic Stroke, Acute Liver Failure, Acute Lung Injury, Acute Pain, Alcohol Addiction, Amyotrophic Lateral Sclerosis, Autoimmune Disorders, Bacterial Sepsis, Burns, Cervical Cancer, Chronic Back Pain, Chronic Liver Disease, Complicated Intra-Abdominal Infections, Crohn's Disease (Regional Enteritis), Ebolavirus Infections (Ebola Hemorrhagic Fever), Endotoxemia, Epilepsy, Escherichia coli Infections, Follicular Lymphoma, Globoid Cell Leukodystrophy (Krabbe Disease), Hearing Disorders, Human Papillomavirus (HPV) Associated Cancer, Inflammatory Bowel Disease, Ischemia Reperfusion Injury, Keratoconjunctivitis sicca (Dry Eye), Leishmaniasis (Kala-Azar), Listeriosis, Low Back Pain, Lung Cancer, Marburgvirus Infections (Marburg Hemorrhagic Fever), Melanoma, Merkel Cell Carcinoma, Metastatic Melanoma, Migraine, Multiple Sclerosis, Necrotizing Enterocolitis, Neuropathic Pain, Non Alcoholic Fatty Liver Disease (NAFLD), Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer), Opium (Opioid) Addiction, Opium Withdrawal Syndrome, Osteoarthritis, Ovarian Cancer, Pain, Pancreatic Cancer, Peanut Allergy, Phlebovirus Infections, Post-Traumatic Stress Disorder (PTSD), Postherpetic Neuralgia, Primary Progressive Multiple Sclerosis (PPMS), Prostate Cancer, Pseudomonas aeruginosa Infections, Pulmonary Edema, Pulmonary Inflammation, Recurrent Glioblastoma Multiforme (GBM), Rhinitis, Rosacea, Secondary Progressive Multiple Sclerosis (SPMS), Septic Shock, Solid Tumor, Trauma, Wounds, Xerostomia and Zika Virus Infections.

The latest report Toll Like Receptor 4 - Pipeline Review, H2 2018, outlays comprehensive information on the Toll Like Receptor 4 (hToll or CD284 or TLR4) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Toll Like Receptor 4 (hToll or CD284 or TLR4) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Toll Like Receptor 4 (hToll or CD284 or TLR4)

- The report reviews Toll Like Receptor 4 (hToll or CD284 or TLR4) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved in Toll Like Receptor 4 (hToll or CD284 or TLR4) targeted therapeutics and enlists all their major and minor projects

- The report assesses Toll Like Receptor 4 (hToll or CD284 or TLR4) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news and deals related to Toll Like Receptor 4 (hToll or CD284 or TLR4) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for Toll Like Receptor 4 (hToll or CD284 or TLR4)

- Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Toll Like Receptor 4 (hToll or CD284 or TLR4) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Toll Like Receptor 4 (hToll or CD284 or TLR4) - Pipeline Review, H2 2018

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Toll Like Receptor 4 (hToll or CD284 or TLR4) - Overview
Toll Like Receptor 4 (hToll or CD284 or TLR4) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Toll Like Receptor 4 (hToll or CD284 or TLR4) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Toll Like Receptor 4 (hToll or CD284 or TLR4) - Companies Involved in Therapeutics Development
AptaTargets SL
Batu Biologics Inc
Bioleaders Corp
Cyxone AB
Eisai Co Ltd
eTheRNA Immunotherapies NV
EyeGene Inc
Formune SL
GigaGen Inc
GlaxoSmithKline Plc
Harbor Therapeutics Inc
Immune Design Corp
Immunovo BV
Kyorin Pharmaceutical Co Ltd
NovImmune SA
Sanofi
TaiwanJ Pharmaceuticals Co Ltd
Takeda Pharmaceutical Co Ltd
Vascular Biogenics Ltd
Toll Like Receptor 4 (hToll or CD284 or TLR4) - Drug Profiles
(clonidine + naltrexone) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ApTOLL - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AyuV-25 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Biologic to Agonize TLR4 for Drug Addiction - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Biologics to Antagonize TLR4 for Dengue Fever - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BLSH-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
C-34 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CIA-05 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CMB-305 + G-100 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CRX-526 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DMT-210 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ECF-843 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ECI-006 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
EDA-HPVE7 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
eritoran tetrasodium - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
G-100 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Inhibit TLR4 for Acute Pain - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GSK-1795091 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HE-3286 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
hp-91 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ibudilast - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ISAS-01 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibodies to Agonize TLR4 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
nalmefene - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
naltrexone - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
naltrexone hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NI-0101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
P-13 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
P-16 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
P-7 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
P-MAPA - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PEPA-10 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
rabeximodum - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
resatorvid - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SAR-439794 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize TLR-4 for CNS Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize TLR2 and TLR4 for Pulmonary Edema, Inflammation and Sepsis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize TLR4 for Acute Lung Injury and Bacterial Sepsis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize TLR4 for Dengue Fever - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptide to Antagonize TLR4 for Sepsis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptide to target TLR-4 for Oncology, Inflammation and Infectious Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TJC-0133 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VB-201 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VB-703 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Toll Like Receptor 4 (hToll or CD284 or TLR4) - Dormant Products
Toll Like Receptor 4 (hToll or CD284 or TLR4) - Discontinued Products
Toll Like Receptor 4 (hToll or CD284 or TLR4) - Product Development Milestones
Featured News & Press Releases
Jun 25, 2018: Immune Design Presents Data on the Mechanism of Action of G100 via TLR4 Expressed in B Cell Malignancies at the Inaugural AACR International Meeting Advances in Malignant Lymphoma
May 24, 2018: eTheRNA Enrols First Patient in High Dose Cohort of Phase 1b study of TriMix mRNA-based Cancer Specific Immunotherapy (ECI-006) in Melanoma
May 09, 2018: MediciNova Announces Opening of Investigational New Drug Application for MN-166 (ibudilast) in Glioblastoma
May 07, 2018: MediciNova Announces Plans to Collaborate with UCLA Researchers in Grant-Funded Clinical Trial of MN-166 (ibudilast) in Alcohol Use Disorder and Withdrawal
Apr 26, 2018: MediciNova Announces Additional Data from Completed Clinical Trial of MN-166 (ibudilast) in ALS Presented at the American Academy of Neurology 70th Annual Meeting
Apr 24, 2018: MediciNova Announces the Presentation of the SPRINT-MS Phase 2b Trial of MN-166 (ibudilast) in Progressive MS at the American Academy of Neurology (AAN) 70th Annual Meeting Plenary Session with Additional Imaging Data
Mar 29, 2018: MediciNova Announces Results of Phase 2 Clinical Trial of MN-166 (ibudilast) in Methamphetamine Dependence
Mar 19, 2018: eTheRNA completes enrolment of low dose cohort for Phase 1b study of TriMix mRNA-based cancer specific immunotherapy (ECI-006) in melanoma
Mar 12, 2018: Immune Design Reports Data Update for Lead Immunotherapy Program: Increased Objective Responses for G100/pembrolizumab Combination in Follicular Lymphoma
Feb 18, 2018: MediciNova Announces Upcoming Presentation of the SPRINT-MS Phase 2b Trial of MN-166 (ibudilast) in Progressive MS at the American Academy of Neurology 70th Annual Meeting
Feb 01, 2018: MediciNova Announces MN-166 (ibudilast) Demonstrated a 26% Reduction in Confirmed Disability Progression in the SPRINT-MS Phase 2b Trial in Progressive MS: Potential Best-in-Disease Drug
Jan 31, 2018: MediciNova Announces Presentation of the SPRINT-MS Phase 2b Study of MN-166 (ibudilast) in Progressive MS at the ACTRIMS Forum
Jan 30, 2018: MediciNova Announces MN-166 (ibudilast) ALS Abstract Accepted for Presentation at the American Academy of Neurology 70th Annual Meeting in Los Angeles, California
Dec 10, 2017: Combination of G100 with KEYTRUDA (pembrolizumab) Triggers Robust Systemic Responses in Follicular NHL Patients
Dec 07, 2017: MediciNova Announces Positive Top-Line Results from the Clinical Trial of MN-166 (ibudilast) in ALS
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Indications, H2 2018
Number of Products under Development by Indications, H2 2018 (Contd..1), H2 2018
Number of Products under Development by Indications, H2 2018 (Contd..2), H2 2018
Number of Products under Development by Indications, H2 2018 (Contd..3), H2 2018
Number of Products under Development by Companies, H2 2018
Number of Products under Development by Companies, H2 2018 (Contd..1)
Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018 (Contd..1), H2 2018
Products under Development by Companies, H2 2018 (Contd..2), H2 2018
Products under Development by Companies, H2 2018 (Contd..3), H2 2018
Number of Products under Investigation by Universities/Institutes, H2 2018
Products under Investigation by Universities/Institutes, H2 2018
Products under Investigation by Universities/Institutes, H2 2018 (Contd..1), H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Pipeline by AptaTargets SL, H2 2018
Pipeline by Batu Biologics Inc, H2 2018
Pipeline by Bioleaders Corp, H2 2018
Pipeline by Cyxone AB, H2 2018
Pipeline by Eisai Co Ltd, H2 2018
Pipeline by eTheRNA Immunotherapies NV, H2 2018
Pipeline by EyeGene Inc, H2 2018
Pipeline by Formune SL, H2 2018
Pipeline by GigaGen Inc, H2 2018
Pipeline by GlaxoSmithKline Plc, H2 2018
Pipeline by Harbor Therapeutics Inc, H2 2018
Pipeline by Immune Design Corp, H2 2018
Pipeline by Immunovo BV, H2 2018
Pipeline by Kyorin Pharmaceutical Co Ltd, H2 2018
Pipeline by NovImmune SA, H2 2018
Pipeline by Sanofi, H2 2018
Pipeline by TaiwanJ Pharmaceuticals Co Ltd, H2 2018
Pipeline by Takeda Pharmaceutical Co Ltd, H2 2018
Pipeline by Vascular Biogenics Ltd, H2 2018
Dormant Products, H2 2018
Dormant Products, H2 2018 (Contd..1), H2 2018
Dormant Products, H2 2018 (Contd..2), H2 2018
Dormant Products, H2 2018 (Contd..3), H2 2018
Discontinued Products, H2 2018

List of Figures
Number of Products under Development by Stage of Development, H2 2018 8
Number of Products under Development by Therapy Areas, H2 2018 9
Number of Products under Development by Top 10 Indications, H2 2018 10
Number of Products by Mechanism of Actions, H2 2018 18
Number of Products by Stage and Mechanism of Actions, H2 2018 18
Number of Products by Routes of Administration, H2 2018 20
Number of Products by Stage and Routes of Administration, H2 2018 20
Number of Products by Molecule Types, H2 2018 22
Number of Products by Stage and Molecule Types, H2 2018 22
  • Global Pandemic Influenza Vaccine Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2023
    Published: 21-Sep-2018        Price: US 3480 Onwards        Pages: 122
    Influenza vaccines treat influenza by developing antibodies in the body within two weeks after vaccination. These antibodies protect against infections with the help of the attenuated viruses in the vaccine. These vaccines contain killed or inactivated strains of the influenza virus. Scope of the Report: This report focuses on the Pandemic Influenza Vaccine in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa.......
  • Global Patent Medicine Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2023
    Published: 21-Sep-2018        Price: US 3480 Onwards        Pages: 120
    Today many drug companies which have produced drugs with which the public is very familiar, like Plavix®, Lipitor® and Abilify® Scope of the Report: This report focuses on the Patent Medicine in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application. The worldwide market for Patent Medicine is expected to grow ......
  • Global Personal Care Products for Maternity Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2023
    Published: 21-Sep-2018        Price: US 3480 Onwards        Pages: 120
    Personal care products for the maternity market are a sub-segment of the overall personal care market based on product use by a specific target audience. Scope of the Report: This report focuses on the Personal Care Products for Maternity in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application. The increasing ......
  • Global Vitamin Ingredients Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2023
    Published: 21-Sep-2018        Price: US 3480 Onwards        Pages: 139
    Vitamins are of two sorts — water soluble (A, D, E, and K) and fat soluble (vitamin B and vitamin C). Vitamin B can be of the following types B1 (thiamine), B2(riboflavin), B3 (niacin), B5 (pantothenic), B6, B12, B9, and B7. The chemical ingredients that constitute vitamins are called vitamers. Vitamins can contain multiple vitamers. For example, Vitamin A contains six vitamers — retinal, retinol, and four types of carotenoids. Human body does not produce vitamin by itself, so human beings depen......
  • 2018-2023 Global Herbal Medicine Consumption Market Report
    Published: 20-Sep-2018        Price: US 4660 Onwards        Pages: 177
    In this report, LP Information covers the present scenario (with the base year being 2017) and the growth prospects of global Herbal Medicine market for 2018-2023. Herbal medicine--also called botanical medicine or phytomedicine refers to using a plant's seeds, berries, roots, leaves, bark, or flowers for medicinal purposes. Herbalism has a long tradition of use outside of conventional medicine. It is becoming more mainstream as improvements in analysis and quality control along w......
  • Global Physiotherapy Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2023
    Published: 20-Sep-2018        Price: US 3480 Onwards        Pages: 120
    Physiotherapy is a nonsurgical treatment method, where the treatment for impairments such as injury, deformity. Scope of the Report: This report focuses on the Physiotherapy in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application. The increasing use of portable physiotherapy equipment in sports will drive the ......
  • Global Wound Cleaning Market Insights, Forecast to 2025
    Published: 20-Sep-2018        Price: US 3900 Onwards        Pages: 96
    This report studies the global market size of Wound Cleaning in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Wound Cleaning in these regions. This research report categorizes the global Wound Cleaning market by players/brands, region, type and application. This report also studies the global market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities a......
  • Global Gastrointestinal Therapeutics and Diagnostics Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2023
    Published: 20-Sep-2018        Price: US 3480 Onwards        Pages: 117
    Gastrointestinal disorders are related to digestive system and generally affect the colon, small & large intestine and rectum. The disorders include constipation, peptic ulcer diseases and irritable bowel syndrome. The major reason and cause of GI disorders are stress, intake of medicines such as iron pills and anti-depressants and unhealthy eating habits. Symptoms of the gastrointestinal infections include pain, bloating, diarrhea, nausea and vomiting. The major drugs that dominate the gastroin......
  • Global Purified Human Proteins Market Insights, Forecast to 2025
    Published: 20-Sep-2018        Price: US 3900 Onwards        Pages: 110
    This report studies the global market size of Purified Human Proteins in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Purified Human Proteins in these regions. This research report categorizes the global Purified Human Proteins market by players/brands, region, type and application. This report also studies the global market status, competition landscape, market share, growth rate, future trends, mark......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs